182 related articles for article (PubMed ID: 12569090)
1. Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity.
Chikamori K; Grabowski DR; Kinter M; Willard BB; Yadav S; Aebersold RH; Bukowski RM; Hickson ID; Andersen AH; Ganapathi R; Ganapathi MK
J Biol Chem; 2003 Apr; 278(15):12696-702. PubMed ID: 12569090
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
3. Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.
Grozav AG; Chikamori K; Kozuki T; Grabowski DR; Bukowski RM; Willard B; Kinter M; Andersen AH; Ganapathi R; Ganapathi MK
Nucleic Acids Res; 2009 Feb; 37(2):382-92. PubMed ID: 19043076
[TBL] [Abstract][Full Text] [Related]
4. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
Ganapathi R; Constantinou A; Kamath N; Dubyak G; Grabowski D; Krivacic K
Mol Pharmacol; 1996 Aug; 50(2):243-8. PubMed ID: 8700130
[TBL] [Abstract][Full Text] [Related]
5. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell resistance to topoisomerase II poisons: role for intracellular free calcium in the sensitization by inhibitors or calcium-calmodulin-dependent enzymes.
Grabowski DR; Dubyak GR; Rybicki L; Hidaka H; Ganapathi R
Biochem Pharmacol; 1998 Aug; 56(3):345-9. PubMed ID: 9744572
[TBL] [Abstract][Full Text] [Related]
7. Retinoic acid and phorbol ester induced hyperphosphorylation of topoisomerase II-alpha is an early event in HL-60 human leukaemia cell differentiation: effect on topoisomerase activity and etoposide sensitivity.
Chresta CM; Hall BF; Francis GE
Leukemia; 1995 Aug; 9(8):1373-81. PubMed ID: 7643627
[TBL] [Abstract][Full Text] [Related]
8. Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast.
Nakazawa N; Arakawa O; Ebe M; Yanagida M
J Biol Chem; 2019 Mar; 294(10):3772-3782. PubMed ID: 30635402
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation-independent stimulation of DNA topoisomerase II alpha activity.
Kimura K; Saijo M; Tanaka M; Enomoto T
J Biol Chem; 1996 May; 271(18):10990-5. PubMed ID: 8631919
[TBL] [Abstract][Full Text] [Related]
10. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
11. Casein kinase II stabilizes the activity of human topoisomerase IIalpha in a phosphorylation-independent manner.
Redwood C; Davies SL; Wells NJ; Fry AM; Hickson ID
J Biol Chem; 1998 Feb; 273(6):3635-42. PubMed ID: 9452492
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle phase-specific phosphorylation of human topoisomerase II alpha. Evidence of a role for protein kinase C.
Wells NJ; Fry AM; Guano F; Norbury C; Hickson ID
J Biol Chem; 1995 Nov; 270(47):28357-63. PubMed ID: 7499337
[TBL] [Abstract][Full Text] [Related]
13. Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2 creates the MPM-2 phosphoepitope on Ser-1469.
Escargueil AE; Plisov SY; Filhol O; Cochet C; Larsen AK
J Biol Chem; 2000 Nov; 275(44):34710-8. PubMed ID: 10942766
[TBL] [Abstract][Full Text] [Related]
14. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
15. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
16. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug, etoposide.
Vassetzky YS; Alghisi GC; Roberts E; Gasser SM
Br J Cancer; 1996 May; 73(10):1201-9. PubMed ID: 8630279
[TBL] [Abstract][Full Text] [Related]
17. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
18. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
20. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
